At Kiniksa Pharmaceuticals International PLC, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of 7.00K shares worth $247.38K, meanwhile ...

Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances ...

We recently compiled a list of the 10 Best UK Growth Stocks to Buy Now. In this article, we are going to take a look at where ...

Y Intercept Hong Kong Ltd acquired a new stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Free Report) in the 4th ...

Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend ...

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report) yesterday and set a price target ...

Kiniksa Pharmaceuticals (NASDAQ:KNSA – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a report issued on Tuesday,RTT News reports. They ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Wells Fargo lowered the firm’s price target on Kiniksa (KNSA) to $30 from $35 and keeps an Overweight rating on the shares. While abiprubart’s ...

Kiniksa Pharmaceuticals, Ltd. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $-0.06. Operator: Good day and thank you for standing by. Welcome to Kiniksa ...

Patel, Chairman and Chief Executive Officer of Kiniksa. “Today, we are excited to announce the development program for KPL-387, which we believe could expand the treatment options for recurrent ...